A once-daily, extended-release form of the amphetamine and dextroamphetamine mixture Adderall (Adderall XR, Shire) has been approved for treatment of attention-deficit/hyperactivity disorder. The new product is supplied in capsules that provide double-pulsed amphetamine delivery, prolonging the amphetamine release compared with immediate-release Adderall.
FDA Sets Date of Advisory Committee Meeting for Donanemab in Alzheimer’s Disease
May 7th 2024The Peripheral and Central Nervous System Drugs Advisory Committee will meet on Monday, June 10, 2024, to discuss the phase 3 trial of Lilly’s donanemab to treat patients with early symptomatic Alzheimer’s disease.